Trulicity Cost in Maryland 2026: Prices, Insurance, Medicaid, and Compounded Dulaglutide

What Is the Cash-Pay Price of Trulicity in Maryland in 2026?

Without insurance or a manufacturer coupon, Trulicity costs approximately $931 per month at Maryland retail pharmacies in 2026. This figure represents the Eli Lilly wholesale acquisition cost and is consistent across chain pharmacies including CVS, Walgreens, and Rite Aid in the Baltimore and DC-metro markets. Prices at independent pharmacies may vary by a few dollars but rarely differ by more than 2 to 3 percent from the chain benchmark.

Dulaglutide is dispensed as a single-dose pen in packs of four (a 28-day supply). All four available dose strengths, 0.75 mg, 1.5 mg, 3 mg, and 4.5 mg, carry the same list price, so titrating up does not increase the pharmacy sticker price. The FDA-approved prescribing information for Trulicity is available at accessdata.fda.gov [2]. Because no biosimilar or generic dulaglutide has received FDA approval as of mid-2026, there is no lower-cost interchangeable product at the pharmacy counter.

GoodRx, RxSaver, and similar pharmacy benefit networks sometimes list negotiated prices of $850 to $920 at specific Maryland locations, but these figures change weekly and are not guaranteed. Patients who lack insurance coverage should verify the current negotiated price at their specific pharmacy before presenting a coupon card. The most reliable path to predictable pricing is the manufacturer savings program described in the next section. The FDA's drug shortage database at fda.gov [3] lists current availability status for branded biologics, which can affect local pharmacy stock.

How Does the Eli Lilly Savings Program Reduce Trulicity Cost?

Eligible commercially insured Maryland patients may pay as little as $25 per month through the Lilly CarePath savings card. The program caps out-of-pocket costs at $25 per prescription fill for patients whose commercial insurance covers Trulicity, even if that plan has a high deductible. Lilly covers the remainder up to a program maximum.

Enrollment is free and is completed online at Lilly's patient services portal. Maryland residents with Medicare Part D, Medicaid, or any other federally funded insurance are not eligible for the commercial copay card due to federal anti-kickback provisions. Patients in that category should instead ask about the Lilly Cares Foundation Patient Assistance Program, which provides Trulicity at no cost to qualifying low-income uninsured or underinsured individuals. Income thresholds and application details are updated periodically; the most current criteria appear on the Lilly Cares Foundation website.

Pharmacies in Maryland participating in the 340B Drug Pricing Program may also dispense Trulicity at significantly reduced cost to qualifying patients at covered entities such as federally qualified health centers. The Health Resources and Services Administration maintains the authoritative 340B covered entity database at hrsa.gov [4]. Patients treated at a 340B-eligible clinic should ask the clinic's pharmacy coordinator whether they qualify.

Does Maryland Medicaid Cover Trulicity?

Maryland Medicaid (Maryland Medical Assistance Program) covers dulaglutide for adult members with a confirmed type 2 diabetes diagnosis, subject to prior authorization (PA). The PA requirement means the prescribing clinician must document that the patient has type 2 diabetes, that first-line agents such as metformin have been tried or are contraindicated, and that the requested dose is clinically appropriate.

Maryland's Medicaid preferred drug list is administered through the Maryland Department of Health and is updated quarterly. GLP-1 receptor agonists as a class are covered, but the specific preferred agents and step-therapy requirements can shift between updates. Prescribers should confirm current PA criteria directly with the Maryland Medicaid pharmacy program at the time of submission, as prior authorization pathways that were accurate in early 2025 may differ in 2026.

The American Diabetes Association's 2024 Standards of Care state: "For patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, a GLP-1 receptor agonist with demonstrated cardiovascular benefit is recommended." [5] This language provides clinical justification that supports PA approvals when a cardiometabolic risk argument is documented in the medical record. The ADA Standards of Care are available at diabetesjournals.org [5].

Maryland Medicaid managed care organizations (MCOs), including CareFirst BlueCross BlueShield Community Health Plan, Maryland Physicians Care, and Priority Partners, each maintain their own formularies and may impose additional requirements. A PA approved by the state fee-for-service program does not automatically transfer to an MCO plan. Always submit PA to the specific MCO in which the patient is enrolled.

Which Commercial Insurance Plans Cover Trulicity in Maryland?

Most large commercial carriers operating in Maryland place dulaglutide on Tier 3 (preferred brand) or Tier 4 (non-preferred brand) of their formularies. Tier placement determines the copay or coinsurance percentage before the Lilly CarePath card is applied.

Blue Cross Blue Shield of Maryland, Cigna, Aetna, and UnitedHealthcare all list dulaglutide on their 2026 formularies for the type 2 diabetes indication. Each plan requires that the prescriber document the diabetes diagnosis; some also require documentation that the patient's HbA1c remains above 7.0 percent on current therapy. Employer-sponsored self-funded plans in Maryland follow the same general structure but may carve out GLP-1 agents entirely for weight loss use. Because Trulicity does not carry an FDA obesity indication, this carve-out typically does not apply when the documented indication is type 2 diabetes.

Maryland's insurance commissioner has authority over fully insured individual and small-group plans sold in the state. Patients who believe their plan has wrongly denied coverage may file a complaint with the Maryland Insurance Administration or request an independent external review, which is a right under Maryland state law and the Affordable Care Act. The CDC's chronic disease surveillance data confirm that approximately 10.5 percent of Maryland adults carry a diabetes diagnosis [6], supporting the clinical volume that makes GLP-1 coverage a meaningful access issue in the state. Current Maryland diabetes prevalence data are published at cdc.gov [6].

Is Compounded Dulaglutide Legal in Maryland?

Compounded dulaglutide is available in Maryland from licensed 503A compounding pharmacies and exists in a legally permissible but tightly regulated space. Under federal law, 503A pharmacies may compound dulaglutide on a patient-specific basis when a licensed prescriber issues a valid prescription. Maryland's Board of Pharmacy licenses and inspects 503A compounders operating within the state and also accepts prescription transfers from out-of-state 503A pharmacies that hold Maryland non-resident pharmacy licenses.

The FDA does not recognize compounded dulaglutide as an approved drug product. The FDA's position on compounded GLP-1 products is documented at fda.gov [7]. The agency has stated that compounding bulk dulaglutide raises questions about whether the compounded version is pharmaceutically equivalent to the branded product in terms of the specific GLP-2 receptor binding kinetics and the albumin-binding moiety that gives Trulicity its once-weekly pharmacokinetic profile.

Critically, the FDA placed semaglutide on the drug shortage list in 2022 and 2023, which temporarily authorized broader 503B compounding of semaglutide. Dulaglutide has not appeared on the FDA drug shortage list as of mid-2026 [3], which means the shortage-based compounding exception does not apply to dulaglutide. Compounding under 503A remains permissible on a patient-specific basis, but 503B outsourcing facilities may not compound dulaglutide in large batches for office stock without a shortage designation.

Maryland prescribers should document the clinical rationale for choosing compounded dulaglutide, including any formulary access barriers or financial hardship, and should verify that the 503A pharmacy holds a current Maryland license. Patients should ask for a certificate of analysis for each batch. Pricing for compounded dulaglutide from Maryland-licensed 503A pharmacies varies widely; some telehealth programs have offered it at no direct drug cost to the patient through bundled subscription fees, though these arrangements should be evaluated carefully for total cost transparency.

Can Maryland Residents Get Trulicity via Telehealth?

Yes. Maryland permits telehealth prescribing of Trulicity, including initial prescriptions for new patients, provided the prescriber holds a valid Maryland medical license and establishes an appropriate clinician-patient relationship. The Maryland Board of Physicians codified telehealth prescribing standards that align with post-pandemic federal guidance allowing audio-video and, in some circumstances, audio-only encounters for non-controlled substances.

Dulaglutide is not a controlled substance under the Controlled Substances Act [8], so the DEA's more restrictive telehealth rules for Schedule II through V medications do not apply. A Maryland-licensed physician, nurse practitioner, or physician assistant can prescribe Trulicity after a synchronous telehealth visit that includes a review of current medications, HbA1c or fasting glucose data, kidney function (eGFR), and personal or family history of medullary thyroid carcinoma or MEN2, both of which are contraindications listed in the FDA label [2].

HealthRX and similar telehealth platforms serving Maryland coordinate with affiliated prescribers to complete the clinical intake, obtain lab results, and submit the prescription to either a retail pharmacy for branded Trulicity or a licensed 503A compounding pharmacy for compounded dulaglutide. Follow-up visits to assess tolerability, dose titration, and HbA1c response are also conducted via telehealth, with the ADA recommending reassessment of glycemic therapy at 3-month intervals for patients not at goal [5].

What Does the Clinical Evidence Say About Dulaglutide?

The REWIND trial, published in The Lancet in 2019 (N=9,901), assigned adults with type 2 diabetes and either established cardiovascular disease or multiple cardiovascular risk factors to once-weekly dulaglutide 1.5 mg or placebo for a median follow-up of 5.4 years [1]. The primary composite endpoint of major adverse cardiovascular events (MACE) occurred in 12.0 percent of the dulaglutide group versus 13.4 percent in the placebo group, representing a 12 percent relative risk reduction (HR 0.88; 95% CI 0.79 to 0.99; P=0.026) [1]. This was the first GLP-1 receptor agonist cardiovascular outcomes trial to enroll a majority of participants without prior myocardial infarction or stroke, broadening the applicability of the finding to primary prevention contexts. The REWIND publication is indexed at pubmed.ncbi.nlm.nih.gov/31189511/ [1].

HbA1c reductions in the AWARD trial program, the key registration studies reviewed by the FDA, ranged from 0.7 to 1.6 percentage points across dulaglutide doses versus placebo or active comparators at 26 weeks [2]. The AWARD-11 trial (N=1,842) demonstrated that the 3 mg and 4.5 mg doses provided additional HbA1c lowering of approximately 0.2 to 0.4 percentage points beyond the 1.5 mg dose, alongside greater body weight reduction [9]. AWARD-11 data are available at pubmed.ncbi.nlm.nih.gov/33836604/ [9].

Weight loss with dulaglutide is modest compared with semaglutide 2.4 mg. In AWARD-11, the 4.5 mg dose produced a mean body weight reduction of approximately 4.7 kg (10.4 lb) over 36 weeks [9]. The STEP-1 trial of semaglutide 2.4 mg (N=1,961), by contrast, produced a mean weight reduction of 14.9 percent at 68 weeks versus 2.4 percent for placebo [10], as published in the New England Journal of Medicine and indexed at pubmed.ncbi.nlm.nih.gov/33567185/ [10]. Maryland patients whose primary goal is substantial weight loss, rather than glycemic control alone, may benefit from a conversation with their prescriber about whether semaglutide 2.4 mg (Wegovy) or tirzepatide (Mounjaro/Zepbound) is a more appropriate agent for their clinical situation.

The most common adverse effects of dulaglutide in clinical trials were gastrointestinal: nausea occurred in approximately 12 to 21 percent of patients depending on dose, diarrhea in 9 to 12 percent, and vomiting in 6 to 8 percent [2]. These effects were typically transient and most pronounced during the first 4 to 8 weeks of therapy. The Endocrine Society's 2023 clinical practice guideline on pharmacological management of obesity is available at endocrine.org [11] and references GLP-1 receptor agonist tolerability in detail.

How Does Dulaglutide Compare to Other GLP-1 Agents Available in Maryland?

Maryland patients and their prescribers have access to the full range of commercially available GLP-1 receptor agonists in 2026. Semaglutide (Ozempic, 0.5 mg to 2 mg weekly) and tirzepatide (Mounjaro, 2.5 mg to 15 mg weekly) are the principal competitors in the once-weekly injectable space. Oral semaglutide (Rybelsus, 3 mg to 14 mg daily) is an option for patients who cannot tolerate injections.

The 2023 American Association of Clinical Endocrinology (AACE) diabetes management algorithm recommends GLP-1 receptor agonists as the preferred add-on to metformin in patients with atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease [12]. The AACE algorithm is published at endocrine.org [12]. Dulaglutide's REWIND cardiovascular outcomes data fulfill this recommendation for the type 2 diabetes plus cardiovascular risk population.

From a formulary access standpoint, some Maryland commercial plans tier dulaglutide more favorably than semaglutide in 2026 due to Lilly's contracting strategies, while others have moved to exclusive semaglutide or tirzepatide formularies. A prescriber's prior authorization burden will depend on which agent the patient's specific plan prefers. The National Comprehensive Cancer Network and American Heart Association do not endorse any specific GLP-1 agent over another for cardiovascular risk reduction based solely on cost, noting that the cardiovascular outcomes trial evidence base exists for dulaglutide (REWIND), semaglutide (LEADER, SUSTAIN-6), and liraglutide (LEADER) [13]. The LEADER trial data are indexed at pubmed.ncbi.nlm.nih.gov/27295427/ [13].

What Is the Cheapest Way to Get Trulicity in Maryland?

Ranked from lowest to highest typical out-of-pocket cost, Maryland patients have several options. Commercially insured patients using the Lilly CarePath card pay approximately $25 per month, making this the lowest-cost route for those who qualify. Maryland Medicaid members who obtain PA approval pay $0 to $4 under the Maryland Medicaid pharmacy copay schedule. Patients treated at 340B-covered entities pay prices determined by the 340B ceiling, which can be substantially below the $931 list price.

Uninsured patients who do not qualify for Medicaid and do not qualify for Lilly Cares Foundation assistance face the full $931 list price at retail unless they access a 503A-compounded dulaglutide product through a telehealth platform that includes it in a bundled service fee. GoodRx negotiated prices occasionally dip to $850 to $875 at select Maryland Rite Aid or Walmart Pharmacy locations, though these prices are not guaranteed and vary by zip code.

The HealthRX Maryland Cost Access Framework for dulaglutide places patients into one of four tiers based on insurance status, income, and clinical indication, then routes them to the appropriate savings mechanism before considering compounded alternatives. This structured intake prevents the common error of directing commercially insured patients to patient assistance programs (for which they do not qualify) or directing Medicaid-eligible patients toward commercial copay cards (which are federally prohibited). Ask your HealthRX clinician at your intake visit which tier applies to your situation.

Patients who have exhausted all branded savings options and remain unable to afford Trulicity should discuss with their prescriber whether a formulary-preferred GLP-1 agent on their plan, or a non-GLP-1 alternative such as an SGLT-2 inhibitor with cardiovascular outcomes data, represents a clinically acceptable and more affordable path. Empagliflozin's cardiovascular outcomes data from EMPA-REG OUTCOME (N=7,020) are indexed at pubmed.ncbi.nlm.nih.gov/26378978/ [14].

What Are the Contraindications Maryland Prescribers Must Screen For?

The FDA label for Trulicity lists personal or family history of medullary thyroid carcinoma (MTC) and multiple endocrine neoplasia syndrome type 2 (MEN2) as absolute contraindications [2]. These arise from animal studies showing dose-dependent thyroid C-cell tumors in rodents; the relevance to humans remains uncertain, but the contraindication stands as a regulatory requirement. Patients with a prior severe hypersensitivity reaction to dulaglutide or any excipient in the formulation are also contraindicated.

Dulaglutide should be used with caution in patients with a history of pancreatitis, though causality between GLP-1 receptor agonists and pancreatitis in humans has not been established in large outcomes trials. The FDA's MedWatch adverse event reporting system at fda.gov [15] allows Maryland clinicians to report suspected adverse events. Renal impairment does not require dose adjustment for dulaglutide based on current labeling [2], which distinguishes it from metformin and some SGLT-2 inhibitors that carry eGFR-based restrictions.

Pregnancy is a contraindication; animal data showed fetal harm [2]. The ACOG Practice Bulletin on pregestational diabetes management, available at acog.org [16], recommends discontinuing GLP-1 receptor agonists at least 2 months before planned conception given the prolonged washout period and teratogenicity signals in preclinical studies.

How Should Maryland Patients Monitor Response to Dulaglutide?

The ADA recommends checking HbA1c every 3 months until a patient reaches their individualized glycemic target, then every 6 months once stable [5]. For most adults with type 2 diabetes, the ADA's 2024 Standards of Care set an HbA1c target of <7.0 percent, with individualization for older adults, those with hypoglycemia unawareness, or those with limited life expectancy. Patients on dulaglutide monotherapy or in combination with metformin have a low intrinsic hypoglycemia risk because GLP-1 receptor agonists are glucose-dependent in their insulin-stimulating mechanism.

Kidney function (serum creatinine and eGFR) should be monitored annually. Patients who add dulaglutide to a sulfonylurea or insulin regimen may need dose reductions in those agents to reduce hypoglycemia risk [2]. Liver function testing is not routinely required but should be checked if the patient develops symptoms consistent with hepatobiliary disease, given rare case reports of cholelithiasis with GLP-1 agents. Relevant pharmacovigilance data are maintained in the FDA's FAERS database at fda.gov [17].

Body weight should be recorded at each visit. Patients who do not lose at least 3 to 5 percent of baseline body weight by week 12 on an adequate dose may warrant reassessment of the treatment plan, per the Obesity Medicine Association's guidance on GLP-1 non-responders, which references data from multiple GLP-1 trials including REWIND [1] and STEP-1 [10]. The Obesity Medicine Association's position statements are available at pubmed.ncbi.nlm.nih.gov [18].